94 related articles for article (PubMed ID: 17690750)
21. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas.
Schützinger C; Esterbauer H; Hron G; Skrabs C; Uffmann M; Raderer M; Hauswirth A; Mannhalter C; Dieckmann K; Wagner O; Formanek M; Stift A; Friedl J; Gaiger A; Chott A; Jäger U
Leuk Lymphoma; 2008 Feb; 49(2):237-46. PubMed ID: 18231909
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome.
Zaja F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Salmaso F; Mariuzzi L; Di Loreto C; Baccarani M
Haematologica; 1997; 82(2):171-7. PubMed ID: 9175321
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
Kobayashi R; Yamato K; Tanaka F; Takashima Y; Inada H; Kikuchi A; Kumagai MA; Sunami S; Nakagawa A; Fukano R; Fujita N; Mitsui T; Tsurusawa M; Mori T;
Pediatr Blood Cancer; 2010 Feb; 54(2):212-5. PubMed ID: 19856396
[TBL] [Abstract][Full Text] [Related]
25. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified.
Beltran BE; Aguilar C; Quiñones P; Morales D; Chavez JC; Sotomayor EM; Castillo JJ
Leuk Lymphoma; 2016; 57(1):58-62. PubMed ID: 25926063
[TBL] [Abstract][Full Text] [Related]
26. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
Sonnen R; Schmidt WP; Müller-Hermelink HK; Schmitz N
Br J Haematol; 2005 May; 129(3):366-72. PubMed ID: 15842660
[TBL] [Abstract][Full Text] [Related]
27. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
[TBL] [Abstract][Full Text] [Related]
28. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group.
Numata A; Miyamoto T; Ohno Y; Kamimura T; Kamezaki K; Tanimoto T; Takase K; Henzan H; Kato K; Takenaka K; Fukuda T; Harada N; Nagafuji K; Teshima T; Akashi K; Harada M; Eto T;
Bone Marrow Transplant; 2010 Feb; 45(2):311-6. PubMed ID: 19597416
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
31. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.
Petrich AM; Helenowski IB; Bryan LJ; Rozell SA; Galamaga R; Nabhan C
Br J Haematol; 2015 Mar; 168(5):708-18. PubMed ID: 25382108
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
33. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
34. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Carson KR; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta MA; Shustov AR; Advani RH; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Cancer; 2017 Apr; 123(7):1174-1183. PubMed ID: 27911989
[TBL] [Abstract][Full Text] [Related]
35. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
36. Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma.
Huang CL; Lin ZZ; Su IJ; Chao TY; Tien HF; Chang MC; Huang MC; Kao WY; Tang JL; Yeh KH; Wang CH; Hsu CH; Liu MY; Cheng AL
Leuk Lymphoma; 2002 Jul; 43(7):1415-20. PubMed ID: 12389622
[TBL] [Abstract][Full Text] [Related]
37. [Expression and clinical significance of nm23-H1 and MUC-1 in peripheral T-cell lymphoma].
Huang HQ; Pan ZH; Lin XB; Wang BF; Hou JH; Zhang Y; Wu QL
Ai Zheng; 2006 Dec; 25(12):1517-23. PubMed ID: 17166378
[TBL] [Abstract][Full Text] [Related]
38. The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P; Rüdiger T; Wilhelm M
Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
[TBL] [Abstract][Full Text] [Related]
39. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
